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Arabi et al. (1) reported the results of their multicentre, 
international  randomised control led tr ia l  (RCT) 
(ISRCTN44653506) of adjunctive Intermittent Pneumatic 
Compression (IPC) for Venous Thromboprophylaxis in N 
Engl J Med in Feb 2019.
Their purpose was to reliably establish whether 
IPC in critically ill patients receiving pharmacologic 
thromboprophylaxis [heparin/low molecular weight 
heparins (LMWH)] would result in a lower incidence of 
deep vein thrombosis (DVT) than heparin/LMWH alone.
Within 48 hours of admission to a critical care unit they 
randomly assigned adult patients to heparin/LMWH plus 
IPC for ≥18 hours each day (intervention) or heparin/
LMWH alone (control). The primary outcome was a new 
proximal DVT, detected on compression Duplex ultrasound 
(CDU) of the deep veins of the legs, carried out twice 
a week, starting on day three after randomization until 
discharge from critical care, death, recovery of mobility, or 
four weeks after randomisation, whichever occurred first.
They randomised 2,003 patients, 991 were randomised n 
to the intervention (IPC) arm and 1,012 to the control arm. 
Adherence was reasonable, IPC was worn for a median of 
22 hours per day for a median of 7 days. A proximal DVT 
was identified in 37 of 957 (3.9%) in the IPC arm and in 41 
of 985 (4.2%) in the control arm [risk ratio (RR) =0.93; 95% 
confidence interval (CI), 0.60 to 1.44; P=0.74]. Pulmonary 
embolism (PE) or any DVT was detected in 103 of 991 
(10.4%) in the IPC arm and in 95 of 1,012 (9.4%) in the 
control arm (RR =1.11; 95% CI, 0.85 to 1.44), and death 
from any cause at 90 days occurred in 258 of 990 (26.1%) in 
the IPC arm and 270 of 1,011 (26.7%), in the control arm 
(RR =0.98; 95% CI, 0.84 to 1.13).
The authors concluded that in patients in critical care 
who were receiving heparin/LMWH, the use of IPC did not 
significantly reduce the risk of venous thromboembolism or 
death compared with heparin/LMWH alone. 
As the lead for the CLOTS trials collaboration, I was 
personally surprised by this result. In 2013, we reported the 
results of the CLOTS3 trial (ISRCTN93529999) (2). We 
aimed to determine if IPC reduced the risk of DVT, PE 
and death in immobile stroke patients admitted to hospital 
in the UK. The background to the CLOTS3 trial was that 
DVT, PE and related deaths were regarded as important 
complications in patients hospitalised with severe stroke 
(3,4). However, previous trials, including a trial of almost 
20,000 patients had shown that whilst prophylactic heparin 
might reduce the risk of DVT and PE, it increased the 
risk of bleeding, and had no net benefit (5,6). Subsequent 
individual patient data meta-analyses could not identify 
any specific subgroup of stroke patients who might benefit 
from prophylactic heparin (7). Also, trials had demonstrated 
that graduated compression stockings did not reduce 
the incidence of DVT in immobile stroke patients (8). A 
systematic review of RCTs in patients undergoing surgery 
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had suggested that IPC reduced the risk of DVT (9). The 
CLOTS3 trial was a multicentre parallel group RCT 
assessing IPC in immobile patients with acute stroke. 
We recruited patients from day 0 to day 3 of admission 
and randomised them to receive IPC or no IPC on a 
background of normal care. A technician who was masked 
to treatment allocation performed a CDU 7 to 10 days 
and, wherever practical, 25 to 30 days after randomisation. 
Patients were followed for 6 months to detect later 
symptomatic VTE and deaths. The primary outcome was 
proximal DVT on a screening CDU or any symptomatic 
DVT in the proximal veins, confirmed on imaging, within 
30 days of randomisation. Patients were analysed according 
to their treatment allocation. We enrolled 2,876 immobile 
stroke patients in 94 centres in the UK. A proximal DVT 
was detected in 122 (8.5%) of 1,438 in the IPC arm and 174 
of 1,438 (12.1%) in the no IPC arm; an absolute reduction 
in risk of 3.6% (95% CI, 1.4 to 5.8) [adjusted risk ratio 0.69 
(95% CI, 0.55 to 0.86); P=0.001)]. Survival to 6 months was 
significantly better in the IPC arm [hazard ratio 0.86 (95% 
CI, 0.74 to 0.99), P=0.042]. We concluded that IPC was 
effective in reducing the incidence of DVT and possibly 
improving survival in patients who are unable to walk 
independently after stroke.
There are no definite explanations for these apparently 
divergent results. Both trials were methodologically similar 
and quite robust. However, compared with CLOTS3, Arabi 
et al. did not attempt to mask those carrying out the CDUs 
which could have led to some expectation bias. However, 
this would generally be expected to lead to an over estimate 
of treatment effect. Also, their follow up protocol, although 
intensive with frequent scanning, was dependent on 
patients’ length of stay in critical care. Ideally, in RCTs 
follow up is to a fixed time point after randomisation, and 
will therefore be similar in the two arms. However, there 
was little difference in the actual duration of follow up 
between the two arms. 
There are other differences between the trials. This trial 
included a far more heterogeneous group of patients in 
terms of their underlying condition—most were admitted 
with medical problems—few were post-surgical or had 
stroke. 
In critical care prophylaxis with heparin/LMWH is 
recommended for those judged to be at low bleeding risk. 
In ischaemic stroke, prophylaxis with heparin/LMWH is 
far more controversial. Previous meta-analyses of trials 
of heparins/LMWH in medical patients, including those 
with stroke (n=36,122) have shown significant reductions 
in pulmonary emboli (three in 1,000, 95% CI, 1 to 3), 
but only non-significant reduction in deaths (six in 1,000, 
95% CI, 0 to 11), perhaps partly because any reduction in 
major VTE was offset by a significant increase in major 
bleeds (four in 1,000, 95% CI, 1 to 7) (10,11). Interestingly, 
studies in critical care mirror these data (12). In this 
trial heparin/LMWH was given to all of the patients 
whereas in CLOTS3 only 21.5% received anticoagulation 
or alteplase—this might contribute to the lower rate 
of proximal DVT (3.9%) and VTE (9.9%) within 28 
days compared with the CLOTS3 trial (10.3%, 19.9% 
respectively within 30 days). 
The sample size of this trial was based on an expected 
absolute risk reduction of 3% from an expected proximal 
DVT rate of 7% in the control arm to 4%, but the actual 
risk was 3.9% across the arms. Therefore, the trial had 
much less power than predicted. The 95% CI of their result 
(95% CI, 0.60 to 1.44), includes the point estimate from 
the CLOTS 3 trial (0.69), so they may simply have been 
underpowered and unlucky, and failed to identify an effect 
similar to that seen in CLOTS3. 
A subgroup analysis of CLOTS3 based on the baseline 
use of alteplase or anticoagulants showed no significant 
interaction with the effect of IPC, however this subgroup 
analysis was underpowered. Given that anticoagulation and 
IPC are presumed to be working on two different sides 
of Wirchow’s triad, I find it difficult to imagine that the 
presence of anticoagulation would negate the effectiveness 
of IPC. However, because of the reduced incidence of VTE 
with anticoagulation, this would make the effect more 
difficult to demonstrate in a randomised trial because the 
event rates would be lower.
Both trials used IPC, but in CLOTS3 all patients had 
thigh-length compression delivered by a single device 
(Covidien SCD Express system) which delivered, sequential, 
circumferential compression at a frequency determined by 
the rate of venous refill. Arabi et al. took a more pragmatic 
approach and did not specify the type of IPC. Only 18.7% 
delivered thigh-length compression, with the remainder 
providing either calf only or foot compression. A range of 
devices will have provided different types of compression. 
There have been no reliable trials to indicate whether 
the type of compression (thigh vs. calf vs. foot; single or 
sequential, circumferential or other, fast or slow, fixed or 
variable frequency) impacts on the effectiveness in reducing 
the risk of VTE, but different manufacturers justify their 
approaches on the basis venous flow rates. 
In conclusion, the neutral result presented by this trial is 
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unexpected. Given the strong evidence that IPC is effective 
in peri operative patients and those with stroke I wonder 
whether lack of sufficient statistical power and perhaps 
the type of IPC used might explain their result. I think it 
would be justified to carry out a larger RCT, testing thigh-
length, sequential IPC in a broad range of high-risk critical 
care patients with and without pharmacological prophylaxis 
before concluding that IPC is ineffective.
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